Formate → 4-{1-[4-(5,5-Dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)thiazol-2-yl]piperidin-4-ylamino}butan-1-ol
Reaction equation
Cl.[CH3:2][C:3]1([CH3:25])[CH2:12][CH2:11][CH2:10][C:9]2[CH:8]=[C:7]([C:13]3[N:14]=[C:15]([N:18]4[CH2:23][CH2:22][CH:21]([NH2:24])[CH2:20][CH2:19]4)[S:16][CH:17]=3)[CH:6]=[CH:5][C:4]1=2.C([O:29][CH2:30][CH2:31][CH2:32][CH2:33]Br)(=O)C.[OH-].[Na+].C([O-])=O>CO>[CH3:2][C:3]1([CH3:25])[CH2:12][CH2:11][CH2:10][C:9]2[CH:8]=[C:7]([C:13]3[N:14]=[C:15]([N:18]4[CH2:23][CH2:22][CH:21]([NH:24][CH2:33][CH2:32][CH2:31][CH2:30][OH:29])[CH2:20][CH2:19]4)[S:16][CH:17]=3)[CH:6]=[CH:5][C:4]1=2Participants
6
Reactant 4
Product 1
Reagents, catalysts & solvents 1
Procedure
The preparation is carried out as described starting from 60 mg (0.16 mmol) of 1-[4-(5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)thiazol-2-yl]piperidin-4-ylamine hydrochloride and 22 μl (0.16 mmol) of 4-bromobutyl acetate. The protecting group is cleaved off by means of a 2N NaOH solution in methanol. The product is in the form of the formate.
Sources & evidence
- ORD record
- ord-b2d2e1157f3441dbbb0f3c5afc4c4116
- Source dataset
- uspto-grants-2014_12
- Patent number
- US08907098B2
Reaction notes
Loading…